M Umar Fareed
Bakhtawar Amin Medical and Dental College, Multan
Abdul Rafay
Bakhtawar Amin Medical and Dental College, Multan
Hamza Rafiq
Multan Medical and Dental College, Multan
Khawaja Faseeh Ahsan
Bakhtawar Amin Medical and Dental College, Multan
Zaira Ahsan
Bakhtawar Amin Medical and Dental College, Multan
ABSTRACT
Pattern hair loss (PHL) occurs in both men (MPHL) and women (FPHL). Some studies estimate that about 50% of males will develop PHL by the time they turn fifty, and that percentage increases to over 70% by the time they turn eighty. The original purpose of minoxidil was to treat hypertension. This treatment mentioned hypertrichosis as a side effect, and this hair loss application was developed. The only medication known to work for both men and women is topical minoxidil, but it remains uncertain how it actually works. Twenty or so years ago, there wasn't any certain treatment or cure for balding in men or women. The pathophysiology of this common disorder was unknown till 1940. Hair cycle has a few phases, e.g, anagen, catagen, telogen, early to mid-anagen (regrowing phase) and again anagen (new growing phase). In other words, there is a "final common pathway" of follicular miniaturization, meaning that the follicular alterations in MPHL and FPHL appear to be the same regardless of the origin. This entails a notable reduction in anagen length. Dermatological Assessment includes hair thinning, hair fall tests, and hair pull tests. Treatments include the use of minoxidil and surgical treatment. The genes involved in hair fall are Wnt/β-catenin signaling pathway, EDA2R on the X chromosome.
Keywords: Pattern Hair Loss (PHL), Genetic Hair Loss, Male Pattern Hair Loss (MPHL), Female Pattern Hair Loss (FPHL), Wnt/Β-Catenin Pathway Genetics, Minoxidil, Anagen Duration, Hair Regrowth, Hair Loss Pathophysiology, Dermatological Assessment, Treatment for Hair Loss, Hair Follicle, Hypertrichosis Side Effect.
